ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 619

Effect of ERAP1 Knockdown on Conformation of HLA-B27 and Other HLA Class I Molecules in Human Monocytic Cells

Tri M. Tran1, Sohee Hong1, Jehad H. Edwan2 and Robert A. Colbert1, 1NIAMS/NIH, Bethesda, MD, 2NIAMS NIH, Bethesda, MD

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), human leukocyte antigens (HLA) and monocytes

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose Polymorphisms in endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) are associated with ankylosing spondylitis, Behcet’s disease, and psoriasis/psoriatic arthritis, where HLA class I alleles are also implicated in susceptibility. The mechanism by which ERAP1 influences disease is unknown, although ERAP1 trims peptides that are presented by HLA class I. To better define the functional interaction between ERAP1 and HLA-B27 we examined the effect of knocking down ERAP1 (ERAP1 KD) on the conformation of HLA-B27 in human monocytic U937 cells (U937.B27) that also express HLA-A3/31, HLA-B18/51, HLA-C1/7).

Methods U937.B27 cells stably expressing shRNA for ERAP1 showed a 65% reduction in ERAP1 protein expression. The unfolded and folded forms of HLA class I molecules (including HLA-B27) were assessed by immunoprecipitation with antibodies HC10 and W6/32, respectively, followed by either isoelectric focusing to separate HLA class I heavy chains, or SDS-PAGE under non-reducing or reducing conditions, to assess disulfide-linked (misfolded) complexes of HLA-B27. HLA proteins were visualized by immunoblotting with 3B.10.7. Flow cytometry was employed to measure expression of folded forms of HLA-B27 (HLA.ABC.m3 or ME1), unfolded and folded forms of HLA class I (HC10 and W6/32, respectively), on the cell surface or after permeabilization (cell surface and intracellular). MARB4, which recognizes a subset of HLA-B27 containing longer peptides and also dimers was also used.

Results

The HLA-B27-transfected U937 cells express approximately equal amounts of HLA-B27 and B51 heavy chains, which is greater than the HLA-B18 allele. At steady state, ERAP1 KD resulted in 47% more folded HLA-B27 accumulating on the cell surface (HLA-ABC.m3) and 30% more in total (extra- plus intracellular), whereas there was only an 11% increase in total folded HLA class I (W6/32). When other alleles were examined by focusing, there was no increase in folded forms of HLA-B51 or B18. MARB4-reactive HLA-B27 was increased by 24% on the cell surface in ERAP1 KD cells. ERAP1 KD caused a 53% increase in unfolded HLA class I (B/C) on the cell surface, and led to a 39% increase in the accumulation of high molecular weigh disulfide-linked complexes of HLA-B27 (immunoblots) (P < 0.05 for all comparisons).

When cells were treated with IFNg, ERAP1 KD caused a 25% increase in total unfolded HLA-B27 compared to sc shRNA, but no increase in HLA-B51 or B18. High molecular weigh disulfide-linked complexes of HLA-B27 were also increased.

Conclusion These data demonstrate that reduction of ERAP1 expression significantly increases both folded and unfolded/misfolded forms of HLA-B27. IFNg treatment further increased all forms of HLA-B27 when ERAP1 expression was limited. It is of interest that the effects of ERAP1 KD on HLA-B allele conformation were substantially greater for HLA-B27 than for Behcet’s disease associated HLA- B51.


Disclosure:

T. M. Tran,
None;

S. Hong,
None;

J. H. Edwan,
None;

R. A. Colbert,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-erap1-knockdown-on-conformation-of-hla-b27-and-other-hla-class-i-molecules-in-human-monocytic-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology